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4-Bromo-3-O-triﬂyl-estrone has been synthesized in 2 steps from estrone and was successfully
employed in chemoselective palladium catalysed Suzuki-Miyaura reactions. Mono- and bis-arylations
were carried out selectively by variation of ligands and solvents. Overall 19 derivatives of mono- and
bis-arylated estrones were synthesized under optimized conditions in high yields. Various products
showed atropisomerism which was studied in detail by NMR spectroscopy.
© 2018 Published by Elsevier Ltd.1. Introduction
Steroids are wide-spread in nature and play a major role in the
regulation of many processes of the human body. Cholesterol, for
example, is an important structural component of the cell mem-
brane.1 Cortisol has various functions in the lipometabolism and in
the metabolism of carbohydrates and furthermore suppresses the
immune system.2 Androgenic and estrogenic steroids function as
sex hormones of human males and females. Estrone, estradiol and
estriol are the three major estrogens3 and their functionalized de-
rivatives have found many applications in pharmaceutical
research.4 These derivatives are widely applied as inhibitors of the
estrogenic receptor as well as imaging agents in the treatment of
breast cancer.5
We have previously shown that 3-alkynylestrones6 and 4-
arylestrones7 are potent phosphatase and lipase inhibitors,
respectively. As part of our ongoing interest in the application of
palladium catalysed reactions on estrones8 we thus decided to
work on 4-bromo-3-O-triﬂyl-estrone as an interesting new startingstitute of Chemistry, Albert-
nger).material in such reactions. Our main interest in this work was to
investigate the chemoselectivity of the coupling reaction. In fact, to
the best of our knowledge, chemoselective palladium catalysed
Suzuki-Miyaura reactions have not been reported on estrones so
far.2. Results and discussion
Estrone 1 was converted into 4-bromoestrone 2 by a known
procedure in a moderate yield of 44%.9 A major side-product of this
reaction is 2,4-dibromoestrone, which can be isolated in a yield of
27%. 4-Bromoestrone 2 was then converted into its corresponding
triﬂate 3 in 95% yield (Scheme 1). The structure of 3 was inde-
pendently conﬁrmed by X-ray crystal structure analysis (Fig. 1).
With starting material 3 in hand, we studied the chemoselective
arylation by palladium catalysed Suzuki-Miyaura reactions
(Table 1). To our delight the initial test reaction using Pd(PPh3)4 as
catalyst gave the mono-arylated product 4a in very good yield
(89%), even though 3 equivalents of arylboronic acid were used.
Only 10% of bis-arylated product 5a was formed under these con-
ditions. The analysis of the products by 19F NMR proved that the
bromine atom is substituted ﬁrst and the triﬂate group second. We
obtained even higher yields of 92 and 98% changing the catalyst to
Fig. 1. ORTEP of starting material 3 (disordered atoms of the triﬂate group have been
omitted for clarity).10
Scheme 1. Synthesis of the starting material 3; i: 1 (3.6mmol), N-bromoacetamide (3.6mmol), ethanol (50mL), r.t., 24 h; ii: 2 (3.0mmol), DMAP (0.6mmol), 2,6-lutidine
(5.7mmol), DCM (30mL), 0 C, then Tf2O (3.6mmol), r.t., 4 h.
S. Jopp et al. / Tetrahedron 74 (2018) 2825e28362826Pd(OAc)2 and using P(Cy)3 or cataCXium® A as ligands, respectively.
On the other hand, SPhos proved to be the ligand of choice for bis-
arylation, achieving product 5a in a high yield of 88% using toluene
as the solvent. Furthermore, a change of the solvent to dioxane gave
a nearly quantitative yield of 5a (99%). The different reactivity of
cataCXium® A and SPhos might result from steric effects and in-
teractions between ligand and substrate. While cataCXium® A
might be too sterically encumbered for a second substitution, the
aromatic moiety of SPhos is able to rotate out of plane and can
furthermore interact with the phenyl-ring of the mono-substituted
substrate.
With our optimized conditions in hand, we analysed the scope
of the mono-fold Suzuki-Miyaura reaction (Table 2). First, we
investigated the impact of steric hindrance. para-MethoxyTable 1
Optimization of the chemoselective Suzuki-Miyaura reaction.a
Catalyst [mol%] Ligand [mol%] Equivalents boronic a
Pd(PPh3)4 [5] e 3.0
Pd(OAc)2 [5] P(Cy)3 [10] 3.0
Pd(OAc)2 [5] cataCXium® A [10] 3.0
Pd(OAc)2 [5] cataCXium® A [10] 1.5
Pd(OAc)2 [5] SPhos [10] 3.0
Pd(OAc)2 [5] SPhos [10] 3.0
a Reaction conditions i: 3 (0.21mmol), 4-methoxyphenylboronic acid, K3PO4 (0.63mmsubstituted product 4a was obtained in a high yield of 98%, while
themeta-product 4b showed a slightly diminished yield of 84% and
was isolated as a mixture of atropisomers (vide infra). The ortho-
product 4c, however, was not formed at all. In general, all products
were isolated in high yields of 84e99%, including those containing
electron-donating and electron-withdrawing groups, like OMe, tBu
and CF3, as well as the heterocyclic thienyl group. Only the strongly
electron-withdrawing cyano group led to a low yield of 35% for
product 4g. A vinyl-groupwas toleratedwithout the occurrence of a
potential Heck reaction as a side reaction, leading to product 4h in
96% yield. All reactions showed a high selectivity towards the
mono-arylated products 4a-i. No formation of bis-arylated prod-
ucts was observed, however, a common side-product is the deha-
logenated startingmaterial 3, which was detected in small amounts
in some reactions. For all products 4a-h a rotational hindrance was
observed by 1H and 13C NMR (vide infra).
As the next step, we compared the results of the mono-arylation
with the synthesis of bis-arylated products 5a-h (Table 3). The
twofold Suzuki-Miyaura reaction of our starting material 3 works
generally in very high yields. All products, independant from the
type of functional group used, were isolated in high yields
(91e99%). The only exception in our tests was the cyano group as
product 5fwas not formed, although themono-arylated product 4g
could be isolated in 34% yield.
Similar to the other products, meta-substituted product 5b was
isolated as a mixture of atropisomers. In fact, a rotational hindrance
was observed for all products (5a-g) in both 1H and 13C NMR.While
the aryl ring in position 3 rotates freely, rotation of the aromaticcid Solvent Yield 4a [%] Yield 5a [%]
toluene 89 10
toluene 92 0
toluene 98 0
toluene 98 0
toluene 12 88
dioxane 0 99
ol), Pd-catalyst, ligand, solvent (4mL), 100 C, 20 h; isolated yields.
Table 2
Synthesis of compounds 4a-i.a
Table 3
Synthesis of compounds 5a-h.a
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Fig. 2. Sterical hindrance through interaction of the CH2-group in position 6 and the
ortho-protons of the aromatic ring.
S. Jopp et al. / Tetrahedron 74 (2018) 2825e2836 2829ring in position 4 is hampered by the corresponding B-ring protons
in position 6 of the steroid scaffold (Fig. 2). The same effect was
observed for compounds 4a-h. Hence, we investigated this effect by
1H NMR studies in DMF-d7 for compound 5c at elevated temper-
atures (Figs. 3 and 4). Interestingly, rotational hindrance was not
completely overcome even at 130 C. However, the transition from
magnetically inequivalent protons of the aromatic ring in position 4
into magnetically equivalent protons at higher temperatures is
obvious. Furthermore product 5b has been investigated by 1H NMR
at elevated temperatures in DMSO-d6 and by HPLC. The atropiso-
merism was overcome at 80 C for this compound (see Supporting
Information). The HPLC measurement showed one peak, most
likely due to the high similarity of both isomers.Fig. 3. 1H NMR of product 5c in DMF-d7 at 25 C, the positions of the aromatiThe structure of 5c was also independently conﬁrmed by X-ray
crystal structure analysis (Fig. 5). The structure shows that the
phenyl ring in position 4 is twisted in an angle of 90 from the
aromatic A-ring of the estrone, while the phenyl ring in position 3
shows an angle of around 45.
Finally, we investigated the synthesis of 3,4-bis-arylated es-
trones containing two different aryl groups (Table 4). We used
mono-arylated product 4d as starting material, as this product
could be easily obtained in a 500mg scale, maintaining a high yield
of 99%. 4d was coupled with four electronically different arylbor-
onic acids, containing a CF3, OMe and vinyl group as well as a
thienyl ring. In comparison to the direct bis-arylation, the mixed
secondary arylation of 4d showed lower yields of 70e97%. How-
ever, mixed bis-arylated products containing electronically
different substituents, such as 6a containing a tert-butyl and a CF3
group, are readily available through this type of reaction. This paves
the way to a broad number of potential products.
We furthermore applied compound 4d in a Sonogashira reac-
tion, using a procedure of our previous work on estrones (Scheme
2).6 Product 7 has been synthesized in 58%. The sterical hindrance
of the phenyl ring located at position 4most likely is responsible for
the only moderate yield of 58%.
3. Conclusion
In conclusion, 4-bromo-3-trifyl-estrone 3 has been successfully
employed in chemoselective palladium catalysed Suzuki-Miyaura
reactions for the ﬁrst time. The synthesis of mono- and bis-c protons were determined via COSY, NOESY, HSQC- and HMBC-2D-NMR.
Fig. 4. 1H NMR of product 5c in DMF-d7 at 25 C, 100 C and 130 C.
S. Jopp et al. / Tetrahedron 74 (2018) 2825e28362830arylated products is selectively controllable by the choice of ligand.
The reaction is generally applicable for many types of electron-rich,
electron-withdrawing and heterocyclic groups in very high yields.
Overall 19 new examples of mono-, bis-, and mixed bis-arylated
products have been synthesized with our optimized conditions,
with one further example showing a mixed Suzuki and Songashira
product, paving the way for a high number of different estrogenic
compounds with potential biological activity.
4. Experimental section
4.1. General
For NMR spectra the substrates were dissolved in CDCl3 orFig. 5. ORTEP of bis-arylated product 5c (the disordered atoms of the tert-butyl groups
have been omitted for clarity).10DMSO-d6 and the spectra were recorded on a Bruker AVANCE 300
III, 250 II or 500. The IR spectra were measured as ATR experiments
with a Nicolet 6700 FT-IR spectrometer and a Nicolet 550 FT-IR
spectrometer. MS and HRMS were measured by an Agilent
6890 N/5973 GC-MS and an Agilent 1200/6210 Time-of-Flight LC-
MS. Melting points were determined by a Micro-Hot-Stage
GalenTM III Cambridge Instruments.
4.1.1. 4-Bromo-3-hydroxy-13b-estra-1,3,5(10)-trien-17-one [2]
Estrone 1 (3.6mmol, 973mg) and N-bromoacetamide
(3.6mmol, 497mg) were dissolved in ethanol (50mL) and stirred
at room temperature for 24 h. The precipitate was ﬁltrated and
dried to yield 2 as a white solid (548mg, 44%). 2,4-Dibromo-3-
hydroxy-13b-estra-1,3,5(10)-trien-17-one (421mg, 27%) can be
isolated as side-product from the ﬁltrate by column chromatog-
raphy (heptane/ethyl acetate 5:1). mp. 263e265 C. 1H NMR
(300MHz, DMSO-d6): d¼ 0.80 (s, 3H, CH3); 1.27e1.58 (m, 6H,
CHAlkyl); 1.71e1.75 (m, 1H, CHAlkyl); 1.91e2.17 (m, 4H, CHAlkyl);
2.29e2.44 (m, 2H, CHAlkyl); 2.56e2.66 (m, 1H, CHAlkyl); 2.82e2.90
(m,1H, CHAlkyl); 6.75 (d, 3J¼ 8.47 Hz, 1H, CHAr); 7.10 (d, 3J¼ 8.48 Hz,
1H, CHAr); 9.84 (s, 1H, OH). 13C NMR (75MHz, DMSO-d6): d¼ 13.4
(CH3); 21.1, 25.7, 26.2, 30.7, 31.3, 35.4 (CH2); 37.0, 43.5 (CH); 47.2 (C);
49.4 (CH); 112.5 (CAr); 113.2, 124.9 (CHAr); 132.2, 136.3, 151.9 (CAr);
219.6 (C]O). IR (ATR, cm1): ~n ¼ 3417 (m), 2917 (m), 1728 (s), 1594
(w), 1475 (s), 1407 (m), 1162 (s), 819 (m), 534 (s).MS (EI, 70 eV):m/z
(%)¼ 351 (21), 350 (Mþ, 81Br, 100), 349 (19), 348 (Mþ, 79Br, 98), 291
(30), 250 (34), 238 (30), 237 (31), 226 (31), 224 (39), 158 (50), 157
(54), 145 (51), 144 (72), 132 (45), 131 (51), 128 (57), 127 (39), 115
(97), 97 (39), 91 (42), 79 (33), 77 (45), 67 (48), 55 (61), 41 (67).
HRMS (EI, 70 eV): Calculated for C18H21BrO2 (79Br, Mþ), 348.07194;
measured 348.07133. Calculated for C18H21BrO2 (81Br, Mþ),
350.06990; measured 350.06966.
Table 4
Synthesis of compounds 6a-d.a
S. Jopp et al. / Tetrahedron 74 (2018) 2825e2836 28314.1.2. 4-Bromo-3-(triﬂuoromethylsulfonyloxy)-13b-estra-1,3,5(10)-
trien-17-one [3]
2 (3.0mmol, 1.048 g), 4-dimethylaminopyridine (DMAP,
0.6mmol, 0.073 g) and 2,6-lutidine (5.7mmol, 0.611 g) were dis-
solved in dichloromethane (30mL) and cooled to 0 C. Tf2O
(3.6mmol, 1.016 g) was added dropwise and the reaction wasScheme 2. Sonogashira reaction of 4d; i: 4d (0.42mmol), phenylacetylene (0.50mmol), diiso
isolated yield.stirred for 4 h, while warming up to room temperature. 1M HCl
(30mL) was added. The organic phase was washed with brine,
dried with Na2SO4 and ﬁltrated. The crude product was puriﬁed by
column chromatography (heptane/ethyl acetate 5:1) to yield 3 as
white solid (1.372 g, 95%). mp. 170e171 C. 1H NMR (250MHz,
CDCl3): d¼ 0.91 (s, 3H, CH3); 1.43e1.65 (m, 6H, CHAlkyl); 1.96e2.23propylamine (1.26mmol), Pd(PPh3)4 (10mol%), CuI (10mol%), DMF (6mL), 100 C, 20 h;
S. Jopp et al. / Tetrahedron 74 (2018) 2825e28362832(m, 4H, CHAlkyl); 2.33e2.58 (m, 3H, CHAlkyl); 2.79e2.86 (m, 1H,
CHAlkyl); 3.01e3.11 (m, 1H, CHAlkyl); 7.14 (d, 3J¼ 8.71 Hz, 1H, CHAr);
7.34 (d, 3J¼ 8.72 Hz, 1H, CHAr). 13C NMR (63MHz, CDCl3): d¼ 13.7
(CH3); 21.5, 25.9, 26.3, 31.2, 31.4, 35.8 (CH2); 37.0, 44.4 (CH); 47.7
(C); 50.3 (CH); 118.6 (q, 1J¼ 320.6 Hz, CF3); 119.0 (CAr); 119.3, 125.6
(CHAr); 139.2, 142.1, 145.2 (CAr); 220.1 (C]O). 19F NMR (235MHz,
CDCl3): d¼73.48. IR (ATR, cm1): ~n ¼ 2934 (w), 1733 (m), 1592
(w), 1403 (m), 1200 (s), 1135 (s), 936 (m), 810 (s), 704 (m), 673 (m),
583 (m).MS (EI, 70 eV):m/z (%)¼ 482 (Mþ, 81Br, 100), 481 (16), 480
(Mþ, 79Br, 96), 438 (30), 436 (29), 425 (17), 423 (23), 331 (40), 329
(39), 305 (34), 303 (28), 293 (47), 291 (51), 268 (47), 237 (24), 226
(21), 212 (17), 211 (30), 141 (16), 129 (22), 128 (34), 115 (44), 97 (29),
77 (18), 69 (65), 55 (20). HRMS (EI, 70 eV): Calculated for
C19H20BrF3O4S (79Br, Mþ), 480.02123; measured 480.02060.
Calculated for C19H20BrF3O4S (81Br, Mþ), 482.01918; measured
482.01909.
4.2. General procedure A for the onefold Suzuki-Miyaura reaction of
3
3 (0.21mmol, 100mg), boronic acid (0.32mmol), K3PO4
(0.63mmol, 132mg), Pd(OAc)2 (5mol%, 2.3mg), cataCXium® A
(10mol%, 7.4mg) and toluene (4mL) were heated in a pressure
tube under argon atmosphere at 100 C for 20 h. The reaction was
quenched with water (5mL) and extracted with ethyl acetate
(3 10mL). The organic phase was dried with Na2SO4 and ﬁltrated.
The crude product was puriﬁed by column chromatography (hep-
tane/ethyl acetate) to yield 4a-i.
4.3. General procedure B for the twofold Suzuki-Miyaura reaction of
3
3 (0.21mmol, 100mg), boronic acid (0.63mmol), K3PO4
(0.63mmol, 132mg), Pd(OAc)2 (5mol%, 2.3mg), SPhos (10mol%,
8.5mg) and dioxane (4mL) were heated in a pressure tube under
argon atmosphere at 100 C for 20 h. The reaction was quenched
with water (5mL) and extracted with ethyl acetate (3 10mL). The
organic phase was dried with Na2SO4 and ﬁltrated. The crude
product was puriﬁed by column chromatography (heptane/ethyl
acetate) to yield 5a-h.
4.4. General procedure C for the Suzuki-Miyaura reaction of 4d
4d (0.187mmol, 100mg), boronic acid (0.281mmol), K3PO4
(0.561mmol, 119mg), Pd(OAc)2 (5mol%, 2.1mg), SPhos (10mol%,
7.7mg) and dioxane (4mL) were heated in a pressure tube under
argon atmosphere at 100 C for 20 h. The reaction was quenched
with water (5mL) and extracted with ethyl acetate (3 10mL). The
organic phase was dried with Na2SO4 and ﬁltrated. The crude
product was puriﬁed by column chromatography (heptane/ethyl
acetate) to yield 6a-d.
4.4.1. 3-(Triﬂuoromethylsulfonyloxy)-4-(4-methoxyphenyl)-13b-
estra-1,3,5(10)-trien-17-one [4a]
4a was synthesized according to general procedure A using 4-
methoxyphenylboronic acid (0.32mmol, 48mg) and was puriﬁed
via column chromatography (heptane/ethyl acetate 5:1) to yield a
yellow oil (104mg, 98%). 1H NMR (250MHz, CDCl3): d¼ 0.93 (s, 3H,
CH3); 1.50e1.65 (m, 6H, CHAlkyl); 1.90e2.17 (m, 4H, CHAlkyl);
2.31e2.57 (m, 5H, CHAlkyl); 3.85 (s, 3H, OCH3); 6.94e7.01 (m, 2H,
CHAr); 7.09e7.17 (m, 3H, CHAr); 7.37 (d, 3J¼ 8.71 Hz, 1H, CHAr). 13C
NMR (63MHz, CDCl3): d¼ 13.8 (CH3); 21.5, 25.9, 26.2, 28.6, 31.5,
35.8 (CH2); 37.3, 44.5 (CH); 47.8 (C); 50.4 (CH); 55.2 (OCH3); 113.7,
118.2 (CHAr); 118.3 (q, 1J¼ 320.3 Hz, CF3); 126.0 (CHAr); 126.5 (CAr);
130.8, 130.9 (CHAr); 134.7, 138.5, 140.5, 145.8, 159.3 (CAr); 220.4 (C]O). 19F NMR (235MHz, CDCl3): d¼74.39. IR (ATR, cm1): ~n
¼ 2928 (w), 1737 (m), 1515 (m), 1465 (m), 1247 (s), 1202 (s), 1138 (s),
1109 (m), 1031 (m), 920 (s), 935 (s), 787 (m), 733 (m), 601 (s). MS
(EI, 70 eV): m/z (%)¼ 509 (14), 508 (Mþ, 58), 375 (25), 212 (16), 211
(100). HRMS (EI, 70 eV): Calculated for C26H27F3O5S (Mþ),
508.15258; measured 508.15245.
4.4.2. 3-(Triﬂuoromethylsulfonyloxy)-4-(3-methoxyphenyl)-13b-
estra-1,3,5(10)-trien-17-one [4b]
4b was synthesized according to general procedure A using 3-
methoxyphenylboronic acid (0.32mmol, 48mg) and was puriﬁed
via column chromatography (heptane/ethyl acetate 5:1) to yield a
yellow oil (88mg, 84%). 1H NMR (300MHz, CDCl3): d¼ 0.93 (s, 6H,
CH3); 1.49e1.65 (m, 12H, CHAlkyl); 1.91e2.17 (m, 8H, CHAlkyl);
2.35e2.60 (m, 10H, CHAlkyl); 3.82 (s, 3H, OCH3); 3.83 (s, 3H, OCH3);
6.74e6.82 (m, 4H, CHAr); 6.93e6.97 (m, 2H, CHAr); 7.16 (d,
3J¼ 8.74 Hz, 2H, CHAr); 7.32e7.40 (m, 4H, CHAr). 13C NMR (63MHz,
CDCl3): d¼ 13.8 (CH3); 21.5, 25.9, 26.1, 28.3, 31.5, 35.8 (CH2); 37.2,
44.5 (CH); 47.8 (C); 50.4 (CH); 55.3, 55.3 (OCH3); 113.6, 113.8, 115.0,
115.3, 118.2 (CHAr); 118.3 (q, 1J¼ 320.1 Hz, CF3); 121.8, 122.0, 126.1,
129.5, 129.6 (CHAr); 134.8, 135.7, 138.0, 138.1, 140.5, 145.3, 159.6,
159.6 (CAr); 220.4 (C]O). 19F NMR (282MHz, CDCl3):
d¼74.36, 74.37. IR (ATR, cm1): ~n ¼ 2929 (w), 1737 (m), 1580
(w), 1417 (s), 1289 (m), 1204 (s), 1138 (s), 1012 (m), 923 (s), 909 (m),
794 (m), 505 (m). MS (EI, 70 eV): m/z (%)¼ 509 (24), 508 (Mþ, 85),
375 (22), 212 (15), 211 (100), 165 (11). HRMS (EI, 70 eV): Calculated
for C26H27F3O5S (Mþ), 508.15258; measured 508.15203.
4.4.3. 3-(Triﬂuoromethylsulfonyloxy)-4-(4-tert-butylphenyl)-13b-
estra-1,3,5(10)-trien-17-one [4d]
4d was synthesized according to general procedure A using 4-
tert-butylphenylboronic acid (0.32mmol, 55mg) and was puriﬁed
via column chromatography (heptane/ethyl acetate 10:1) to yield a
yellow solid (112mg, >99%). mp. 73e74 C. 1H NMR (500MHz,
CDCl3): d¼ 0.93 (s, 3H, CH3); 1.36 (s, 9H, CH3,tBu); 1.47e1.64 (m, 6H,
CHAlkyl); 1.91e2.17 (m, 4H, CHAlkyl); 2.33e2.60 (m, 5H, CHAlkyl);
7.11e7.17 (m, 3H, CHAr); 7.37 (d, 3J¼ 8.38 Hz, 1H, CHAr); 7.43e7.47
(m, 2H, CHAr). 13C NMR (63MHz, CDCl3): d¼ 13.8 (CH3); 21.5, 25.9,
26.2, 28.6 (CH2); 31.3 (CH3,tBu); 31.5 (CH2); 34.6 (CtBu); 35.8 (CH2);
37.3, 44.5 (CH); 47.8 (C); 50.4 (CH); 118.2 (CHAr); 118.3 (q,
1J¼ 320.3 Hz, CF3); 125.2, 125.3, 125.9, 129.2, 129.3 (CHAr); 131.3,
135.0, 138.3, 140.4, 145.6, 151.0 (CAr); 220.5 (C]O). 19F NMR
(282MHz, CDCl3): d¼74.49. IR (ATR, cm1): ~n ¼ 2957 (w), 1739
(m), 1515 (w), 1465 (m), 1418 (s), 1202 (s), 1185 (s), 1138 (s), 1022 (s),
936 (m), 922 (s), 837 (s), 664 (m), 599 (s). MS (EI, 70 eV): m/z
(%)¼ 534 (Mþ, 11), 519 (23), 57 (100). HRMS (EI, 70 eV): Calculated
for C29H33F3O4S (Mþ), 534.20462; measured 534.20471.
4.4.4. 3-(Triﬂuoromethylsulfonyloxy)-4-(4-ﬂuorophenyl)-13b-
estra-1,3,5(10)-trien-17-one [4e]
4e was synthesized according to general procedure A using 4-
ﬂuorophenylboronic acid (0.32mmol, 47mg) and was puriﬁed via
column chromatography (heptane/ethyl acetate 5:1) to yield a
yellow solid (88mg, 85%). mp. 121e122 C. 1H NMR (500MHz,
CDCl3): d¼ 0.93 (s, 3H, CH3); 1.32e1.62 (m, 6H, CHAlkyl); 1.92e2.16
(m, 4H, CHAlkyl); 2.32e2.55 (m, 5H, CHAlkyl); 7.13e7.20 (m, 5H,
CHAr); 7.40 (d, 3J¼ 8.68 Hz, 1H, CHAr). 13C NMR (125MHz, CDCl3):
d¼ 13.8 (CH3); 21.5, 25.9, 26.1, 28.5, 31.5, 35.8 (CH2); 37.3, 44.5 (CH);
47.8 (C); 50.4 (CH); 115.5 (d, 2J¼ 21.6 Hz, CHAr); 115.6 (d,
2J¼ 21.5 Hz, CHAr); 118.3 (CHAr); 118.3 (q, 1J¼ 320.1 Hz, CF3); 126.4
(CHAr); 130.3 (d, 4J¼ 3.48 Hz, CAr); 131.4 (d, 3J¼ 8.25 Hz, CHAr);
131.5 (d, 3J¼ 8.29 Hz, CHAr); 134.0, 138.2, 140.7, 145.4 (CAr); 162.5 (d,
1J¼ 247.5 Hz, C-F); 220.3 (C]O). 19F NMR (282MHz, CDCl3):
d¼74.37 (CF3), 113.70 (C-F). IR (ATR, cm1): ~n ¼ 2873 (w), 1732
(m), 1512 (m), 1466 (m), 1414 (s), 1202 (s), 1159 (m), 1139 (s), 1057
S. Jopp et al. / Tetrahedron 74 (2018) 2825e2836 2833(m), 925 (s), 823 (s), 621 (m), 506 (m).MS (EI, 70 eV):m/z (%)¼ 496
(Mþ, 20), 251 (17), 225 (21), 200 (15), 199 (100), 109 (14), 69 (14).
HRMS (ESI): Calculated for C25H25F4O4S (M þ Hþ), 497.14042;
measured 497.14048.
4.4.5. 3-(Triﬂuoromethylsulfonyloxy)-4-(4-triﬂuoromethylphenyl)-
13b-estra-1,3,5(10)-trien-17-one [4f]
4f was synthesized according to general procedure A using 4-
triﬂuoromethylphenylboronic acid (0.32mmol, 61mg) and was
puriﬁed via column chromatography (heptane/ethyl acetate 5:1) to
yield a yellow oil (103mg, 90%). 1H NMR (300MHz, CDCl3): d¼ 0.95
(s, 3H, CH3); 1.53e1.67 (m, 6H, CHAlkyl); 1.95e2.09 (m, 4H, CHAlkyl);
2.34e2.57 (m, 5H, CHAlkyl); 7.22 (d, 3J¼ 8.76 Hz, 1H, CHAr);
7.34e7.40 (m, 2H, CHAr); 7.45 (d, 3J¼ 8.71 Hz, 1H, CHAr); 7.71e7.76
(m, 2H, CHAr). 13C NMR (63MHz, CDCl3): d¼ 13.8 (CH3); 21.5, 25.9,
26.0, 28.5, 31.5, 35.7 (CH2); 37.2, 44.5 (CH); 47.8 (C); 50.3 (CH); 118.2
(q, 1J¼ 320.4 Hz, CF3); 118.5 (CHAr); 124.0 (q, 1J¼ 272.3 Hz, CeCF3);
125.4 (m, CHAr); 126.8 (CHAr); 129.9 (q, 2J¼ 32.6 Hz, C-CF3); 130.2,
130.3 (CHAr); 133.5, 137.7 (CAr); 138.4 (q, 5J¼ 1.29 Hz, CAr); 140.8,
144.9 (CAr); 220.3 (C]O). 19F NMR (282MHz, CDCl3): d¼62.66
(CF3), 74.37 (CF3). IR (ATR, cm1): ~n ¼ 2931 (w), 1737 (m), 1618
(w),1419 (m),1322 (s),1207 (s),1124 (s),1064 (m), 921 (m), 844 (m),
734 (w), 607 (m). MS (EI, 70 eV): m/z (%)¼ 547 (27), 546 (Mþ, 94),
502 (32), 489 (19), 395 (43), 393 (16), 303 (17), 301 (46), 299 (18),
289 (17), 287 (19), 275 (47), 250 (15), 249 (100), 233 (18), 97 (19), 69
(33), 55 (17). HRMS (EI, 70 eV): Calculated for C26H24F6O4S (Mþ),
546.12940; measured 546.12963.
4.4.6. 3-(Triﬂuoromethylsulfonyloxy)-4-(4-cyanophenyl)-13b-
estra-1,3,5(10)-trien-17-one [4g]
4g was synthesized according to general procedure A using 4-
cyanophenylboronic acid (0.32mmol, 45mg) and was puriﬁed via
column chromatography (heptane/ethyl acetate 5:1) to yield a
white solid (36mg, 35%). mp. 168e169 C. 1H NMR (300MHz,
CDCl3): d¼ 0.93 (s, 3H, CH3); 1.47e1.65 (m, 5H, CHAlkyl); 1.92e2.28
(m, 5H, CHAlkyl); 2.33e2.55 (m, 5H, CHAlkyl); 7.20 (d, 3J¼ 8.77 Hz,1H,
CHAr); 7.33e7.39 (m, 2H, CHAr); 7.45 (d, 3J¼ 8.71 Hz, 1H, CHAr);
7.73e7.79 (m, 2H, CHAr). 13C NMR (63MHz, CDCl3): d¼ 13.8 (CH3);
21.5, 25.9, 26.0, 28.5, 31.5, 35.7 (CH2); 37.2, 44.4 (CH); 47.8 (C); 50.3
(CH); 112.2 (CN); 118.2 (q, 1J¼ 320.2 Hz, CF3); 118.5 (CAr); 118.6,
127.2, 130.7, 130.8, 132.2, 132.4 (CHAr); 133.1, 137.5, 139.6, 141.0,
144.7 (CAr); 220.2 (C]O). 19F NMR (282MHz, CDCl3): d¼74.21. IR
(ATR, cm1): ~n ¼ 2860 (w), 2228 (m), 1735 (m), 1512 (w), 1417 (s),
1205 (s), 1138 (s), 1010 (m), 923 (s), 842 (s), 620 (m), 599 (s).MS (EI,
70 eV): m/z (%)¼ 504 (24), 503 (Mþ, 100), 459 (30), 446 (16), 352
(29), 258 (23), 206 (34). HRMS (EI, 70 eV): Calculated for
C26H24F3NO4S (Mþ), 503.13727; measured 503.13700.
4.4.7. 3-(Triﬂuoromethylsulfonyloxy)-4-(4-vinylphenyl)-13b-estra-
1,3,5(10)-trien-17-one [4h]
4h was synthesized according to general procedure A using 4-
vinylphenylboronic acid (0.32mmol, 47mg) and was puriﬁed via
column chromatography (heptane/ethyl acetate 5:1) to yield a
yellow oil (102mg, 96%). 1H NMR (300MHz, CDCl3): d¼ 0.95 (s, 3H,
CH3); 1.48e1.71 (m, 6H, CHAlkyl); 1.91e2.24 (m, 4H, CHAlkyl);
2.36e2.61 (m, 5H, CHAlkyl); 5.32 (dd, 2J¼ 0.72 Hz, 3J¼ 10.90 Hz, 1H,
CH]CH2,cis); 5.83 (dd, 2J¼ 0.78 Hz, 3J¼ 17.61 Hz,1H, CH]CH2,trans);
6.78 (dd, 3J¼ 17.62 Hz, 3J¼ 10.92 Hz, 1H, CH]CH2); 7.16e7.22 (m,
3H, CHAr); 7.40 (d, 3J¼ 8.91 Hz, 1H, CHAr); 7.48e7.56 (m, 2H, CHAr).
13C NMR (75MHz, CDCl3): d¼ 13.8 (CH3); 21.5, 25.9, 26.1, 28.5, 31.5,
35.8 (CH2); 37.2, 44.5 (CH); 47.8 (C); 50.4 (CH); 114.4 (CH2,Vinyl);
118.2 (CHAr); 118.3 (q, 1J¼ 320.3 Hz, CF3); 126.1, 126.2, 126.3, 129.8,
129.9 (CHAr); 133.9, 134.6 (CAr); 136.4 (CHVinyl); 137.2, 138.1, 140.5,
145.4 (CAr); 220.3 (C]O). 19F NMR (282MHz, CDCl3): d¼74.31. IR
(ATR, cm1): ~n ¼ 2931 (w), 1737 (m), 1710 (s), 1417 (m), 1359 (m),1205 (s), 1139 (s), 921 (m), 842 (m), 603 (m). MS (EI, 70 eV): m/z
(%)¼ 504 (Mþ, 25), 259 (10), 233 (10), 208 (17), 207 (100), 69 (13),
55 (10). HRMS (EI, 70 eV): Calculated for C27H27F3O4S (Mþ),
504.15767; measured 504.15756.
4.4.8. 3-(Triﬂuoromethylsulfonyloxy)-4-(3-thienyl)-13b-estra-
1,3,5(10)-trien-17-one [4i]
4i was synthesized according to general procedure A using 3-
thienylboronic acid (0.32mmol, 47mg) and was puriﬁed via col-
umn chromatography (heptane/ethyl acetate 5:1) to yield a yellow
oil (90mg, 90%). 1H NMR (300MHz, CDCl3): d¼ 0.93 (s, 3H, CH3);
1.47e1.73 (m, 6H, CHAlkyl); 1.94e2.17 (m, 4H, CHAlkyl); 2.33e2.63
(m, 5H, CHAlkyl); 6.99 (dd, 3J¼ 4.93 Hz, 4J¼ 1.25 Hz, 1H, CHHetAr);
7.15 (d, 3J¼ 8.76 Hz, 1H, CHHetAr); 7.21 (dd, 4J¼ 2.94 Hz, 4J¼ 1.25 Hz,
1H, CHHetAr); 7.38 (d, 3J¼ 8.73 Hz, 1H, CHHetAr); 7.43 (dd,
3J¼ 4.95 Hz, 4J¼ 2.95 Hz, 1H, CHAr). 13C NMR (63MHz, CDCl3):
d¼ 13.7 (CH3); 21.5, 25.9, 26.1, 28.4, 31.5, 35.8 (CH2); 37.2, 44.5 (CH);
47.8 (C); 50.4 (CH); 118.3 (CHAr); 118.3 (q, 1J¼ 320.3 Hz, CF3); 124.9,
125.7, 126.3, 128.7 (CHAr); 130.3, 133.7, 138.9, 140.5, 145.8 (CAr);
220.3 (C]O). 19F NMR (235MHz, CDCl3): d¼74.23. IR (ATR,
cm1): ~n ¼ 2860 (w), 1737 (m), 1418 (s), 1250 (m), 1204 (s), 1138 (s),
1013 (m), 922 (s), 829 (m), 605 (m). MS (EI, 70 eV): m/z (%)¼ 485
(20), 484 (Mþ, 75), 351 (100), 187 (40).HRMS (EI, 70 eV): Calculated
for C23H23F3O4S2 (Mþ), 484.09844; measured 484.09770.
4.4.9. 3,4-Bis-(4-methoxyphenyl)-13b-estra-1,3,5(10)-trien-17-one
[5a]
5a was synthesized according to general procedure B using 4-
methoxyphenylboronic acid (0.63mmol, 96mg) and was puriﬁed
via column chromatography (heptane/ethyl acetate 5:1) to yield a
brown solid (99mg, >99%). mp. 168e169 C. 1H NMR (250MHz,
CDCl3): d¼ 0.95 (s, 3H, CH3); 1.53e1.69 (m, 6H, CHAlkyl); 1.92e2.18
(m, 4H, CHAlkyl); 2.42e2.64 (m, 5H, CHAlkyl); 3.73 (s, 3H, OCH3); 3.78
(s, 3H, OCH3); 6.68 (d, 3J¼ 8.61 Hz, 2H, CHAr); 6.72e6.77 (m, 1H,
CHAr); 6.79e6.89 (m, 2H, CHAr); 6.98 (d, 3J¼ 8.60 Hz, 2H, CHAr); 7.04
(dd, 3J¼ 8.32 Hz, 4J¼ 1.97 Hz, 1H, CHAr); 7.24 (d, 3J¼ 8.02 Hz, 1H,
CHAr); 7.39 (d, 3J¼ 8.13 Hz, 1H, CHAr). 13C NMR (63MHz, CDCl3):
d¼ 13.8 (CH3); 21.5, 26.0, 26.6, 29.0, 31.7, 35.8 (CH2); 37.5, 44.8 (CH);
47.9 (C); 50.6 (CH); 55.0, 55.0 (OCH3); 112.9 (2xCHAr); 113.2, 113.3,
124.4, 127.4 (CHAr); 130.7 (2xCHAr); 131.2, 131.3 (CHAr); 132.7, 134.3,
135.3, 138.8, 139.1, 140.0, 157.7, 157.9 (CAr); 220.8 (C]O). IR (ATR,
cm1): ~n ¼ 2924 (m),1737 (s),1608 (m),1510 (m),1241 (s),1107 (m),
1028 (s), 819 (s), 583 (m). MS (EI, 70 eV): m/z (%)¼ 468 (21), 467
(89), 466 (Mþ, 100), 464 (9), 356 (5), 355 (5), 342 (8), 303 (6), 301
(7), 287 (5),121 (7).HRMS (EI, 70 eV): Calculated for C32H34O3 (Mþ),
466.25025; measured 466.25053.
4.4.10. 3,4-Bis-(3-methoxyphenyl)-13b-estra-1,3,5(10)-trien-17-
one [5b]
5b was synthesized according to general procedure B using 3-
methoxyphenylboronic acid (0.63mmol, 96mg) and was puriﬁed
via column chromatography (heptane/ethyl acetate 5:1) to yield a
yellow oil (91mg, 93%). 1H NMR (300MHz, CDCl3): d¼ 0.96 (s, 6H,
2xCH3); 1.51e1.71 (m, 14H, CHAlkyl); 1.93e2.24 (m, 8H, CHAlkyl);
2.44e2.66 (m, 8H, CHAlkyl); 3.60 (s, 3H, OCH3); 3.61 (s, 3H, OCH3);
3.63 (s, 3H, OCH3); 3.73 (s, 3H, OCH3); 6.53e6.54 (m, 1H, CHAr);
6.60e6.63 (m, 3H, CHAr); 6.65e6.69 (m, 2H, CHAr); 6.71e6.80 (m,
6H, CHAr); 7.04e7.22 (m, 4H,CHAr); 7.30 (d, 3J¼ 8.10 Hz, 2H, CHAr);
7.43 (d, 3J¼ 8.20 Hz, 2H, CHAr). 13C NMR (75MHz, CDCl3): d¼ 13.8
(CH3); 21.5, 26.0, 26.6, 28.8, 31.7, 35.8 (CH2); 37.6, 44.8, 44.9 (CH);
47.9 (C); 50.6 (CH); 55.0, 55.1, 55.1, 55.3 (OCH3); 111.9, 112.2, 122.3,
112.4,114.9,115.7,116.0,122.1,122.2,122.8,122.9,124.6,127.3, 128.3,
128.4, 128.6, 128.9 (CHAr); 134.9, 134.9, 139.0, 139.0, 139.3, 140.1,
140.1, 141.7, 141.7, 143.1, 143.1, 158.6, 159.1, 159.2 (CAr); 220.7 (C]O).
IR (ATR, cm1): ~n ¼ 2927 (m), 1735 (s), 1577 (m), 1465 (m), 1207 (s),
S. Jopp et al. / Tetrahedron 74 (2018) 2825e283628341039 (s), 908 (m), 777 (s), 729 (s).MS (EI, 70 eV):m/z (%)¼ 467 (31),
466 (Mþ, 100), 271 (11), 67 (11), 55 (13). HRMS (EI, 70 eV): Calcu-
lated for C32H34O3 (Mþ), 466.25025; measured 466.24979.
4.4.11. 3,4-Bis-(4-tert-butylphenyl)-13b-estra-1,3,5(10)-trien-17-
one [5c]
5c was synthesized according to general procedure B using 4-
tert-butylphenylboronic acid (0.63mmol, 112mg) and was puriﬁed
via column chromatography (heptane/ethyl acetate 10:1) to yield a
white solid (107mg, 98%). mp. 226e227 C. 1H NMR (300MHz,
CDCl3): d¼ 0.96 (s, 3H, CH3); 1.24 (s, 9H, CH3,tBu); 1.28 (s, 9H,
CH3,tBu); 1.53e1.71 (m, 6H, CHAlkyl); 1.94e2.18 (m, 4H, CHAlkyl);
2.40e2.56 (m, 3H, CHAlkyl); 2.64e2.70 (m, 2H, CHAlkyl); 6.85 (dd,
3J¼ 8.04 Hz, 4J¼ 1.86 Hz, 1H, CHAr); 6.94 (d, 3J¼ 8.34 Hz, 2H, CHAr);
7.04 (dd, 3J¼ 8.02 Hz, 4J¼ 1.84 Hz, 1H, CHAr); 7.10 (d, 3J¼ 8.38 Hz,
2H, CHAr); 7.17 (dd, 3J¼ 8.06 Hz, 4J¼ 2.04 Hz, 1H, CHAr); 7.24 (dd,
3J¼ 8.11 Hz, 4J¼ 2.04 Hz, 1H, CHAr); 7.30 (d, 3J¼ 8.08 Hz, 1H, CHAr);
7.41 (d, 3J¼ 8.15 Hz, 1H, CHAr). 13C NMR (75MHz, CDCl3): d¼ 13.9
(CH3); 21.5, 26.0, 26.7, 29.0 (CH2); 31.2, 31.3 (CH3,tBu); 31.7 (CH2);
34.2, 34.4 (CtBu); 35.9 (CH2); 37.6, 44.9 (CH); 48.0 (C); 50.6 (CH);
124.1 (2xCHAr); 124.3, 124.4, 124.5, 127.2 (CHAr); 129.4, 130.0
(2xCHAr); 135.0, 137.3, 138.8, 138.9, 139.6, 140.6, 148.5, 149.0 (CAr);
220.9 (C]O). IR (ATR, cm1): ~n ¼ 2865 (m), 1745 (s), 1467 (m), 1391
(m), 1267 (m), 1114 (m), 837 (m), 598 (m). MS (EI, 70 eV): m/z
(%)¼ 519 (16), 518 (Mþ, 53), 503 (23), 207 (10), 73 (10), 67 (11), 57
(100), 55 (23), 41 (25), 29 (13). HRMS (EI, 70 eV): Calculated for
C38H46O (Mþ), 518.35432; measured 518.35407.
4.4.12. 3,4-Bis-(4-ﬂuorophenyl)-13b-estra-1,3,5(10)-trien-17-one
[5d]
5d was synthesized according to general procedure B using 4-
ﬂuorophenylboronic acid (0.63mmol, 88mg) and was puriﬁed via
column chromatography (heptane/ethyl acetate 5:1) to yield a
white solid (92mg, >99%). mp. 55e56 C. 1H NMR (300MHz,
CDCl3): d¼ 0.95 (s, 3H, CH3); 1.54e1.69 (m, 6H, CHAlkyl); 1.92e2.18
(m, 4H, CHAlkyl); 2.41e2.61 (m, 5H, CHAlkyl); 6.79e6.85 (m, 2H,
CHAr); 6.88e6.92 (m, 2H, CHAr); 6.95e7.00 (m, 3H, CHAr); 7.04e7.09
(m, 1H, CHAr); 7.23 (d, 3J¼ 8.10 Hz, 1H, CHAr); 7.42 (d, 3J¼ 8.09 Hz,
1H, CHAr). 13C NMR (125MHz, CDCl3): d¼ 13.8 (CH3); 21.5, 26.0,
26.6, 29.0, 31.7, 35.8 (CH2); 37.5, 44.8 (CH); 47.9 (C); 50.6 (CH); 114.4
(d, 2J¼ 21.2 Hz, 2xCHAr); 114.8 (d, 2J¼ 21.5 Hz, CHAr); 115.0 (d,
2J¼ 21.5 Hz, CHAr); 124.8, 127.3 (CHAr); 131.2 (d, 3J¼ 7.9 Hz,
2xCHAr); 131.8 (d, 3J¼ 7.8 Hz, 2xCHAr); 135.2 (CAr); 136.0 (d,
4J¼ 3.4 Hz, CAr); 137.6 (d, 4J¼ 3.4 Hz, CAr); 138.5, 139.4, 139.5 (CAr);
161.4 (d, 1J¼ 245.5 Hz, C-F); 161.5 (d, 1J¼ 245.8 Hz, C-F); 220.6 (C]
O). 19F NMR (282MHz, CDCl3): d¼116.66, 115.94. IR (ATR,
cm1): ~n ¼ 2925 (m), 1735 (s), 1602 (m), 1508 (s), 1467 (m), 1218 (s),
1157 (s), 1006 (m), 819 (s), 592 (m). MS (EI, 70 eV): m/z (%)¼ 443
(45), 442 (Mþ, 100), 277 (8). HRMS (EI, 70 eV): Calculated for
C30H28OF2 (Mþ), 442.21027; measured 442.21000.
4.4.13. 3,4-Bis-(4-triﬂuoromethylphenyl)-13b-estra-1,3,5(10)-
trien-17-one [5e]
5e was synthesized according to general procedure B using 4-
triﬂuoromethylphenylboronic acid (0.63mmol, 119mg) and was
puriﬁed via column chromatography (heptane/ethyl acetate 5:1) to
yield a yellow oil (114mg, >99%). 1H NMR (300MHz, CDCl3):
d¼ 0.97 (s, 3H, CH3); 1.55e1.71 (m, 6H, CHAlkyl); 1.96e2.19 (m, 4H,
CHAlkyl); 2.44e2.60 (m, 5H, CHAlkyl); 7.10 (d, 3J¼ 8.06 Hz, 1H, CHAr);
7.14 (d, 3J¼ 7.99 Hz, 2H, CHAr); 7.27 (dd, 3J¼ 7.94 Hz, 4J¼ 3.41 Hz,
2H, CHAr); 7.40 (d, 3J¼ 8.11 Hz, 2H, CHAr); 7.49 (d, 3J¼ 8.08 Hz, 2H,
CHAr); 7.55 (d, 3J¼ 8.01 Hz, 1H, CHAr). 13C NMR (75MHz, CDCl3):
d¼ 13.8 (CH3); 21.5, 26.0, 26.5, 28.9, 31.6, 35.8 (CH2); 37.5, 44.8
(CH); 47.9 (C); 50.5 (CH); 124.1 (q, 1J¼ 272.0 Hz, CF3); 124.1 (q,
1J¼ 272.1 Hz, CF3); 124.6 (q, 3J¼ 3.70 Hz, 2xCHAr); 124.9 (q,3J¼ 3.79 Hz, CHAr); 125.1 (q, 3J¼ 3.83 Hz, CHAr); 125.4, 127.4 (CHAr);
128.5 (q, 2J¼ 32.4 Hz, C-CF3); 128.9 (q, 2J¼ 32.5 Hz, C-CF3); 129.9
(2xCHAr); 130.5, 130.6 (CHAr); 134.9, 137.7, 138.8, 140.2 (CAr); 143.8
(q, 5J¼ 1.18 Hz, CAr); 145.0 (q, 5J¼ 1.17 Hz, CAr); 220.6 (C]O). 19F
NMR (282MHz, CDCl3): d¼62.47. IR (ATR, cm1): ~n ¼ 2930 (m),
1736 (m), 1616 (m), 1320 (s), 1119 (s), 1063 (s), 1017 (m), 821 (m),
731 (m).MS (EI, 70 eV):m/z (%)¼ 543 (45), 542 (Mþ, 100), 498 (31),
485 (24), 432 (18), 429 (24), 377 (22), 359 (15), 270 (19), 79 (18), 69
(18), 68 (15), 67 (16), 55 (43), 43 (19), 41 (23). HRMS (EI, 70 eV):
Calculated for C32H28OF6 (Mþ), 542.20389; measured 542.20447.
4.4.14. 3,4-Bis-(4-vinylphenyl)-13b-estra-1,3,5(10)-trien-17-one
[5g]
5g was synthesized according to general procedure B using 4-
vinylphenylboronic acid (0.63mmol, 93mg) and was puriﬁed via
column chromatography (heptane/ethyl acetate 5:1) to yield a
white solid (92mg, 96%).mp. 72e73 C. 1H NMR (300MHz, CDCl3):
d¼ 0.97 (s, 3H, CH3); 1.51e1.71 (m, 6H, CHAlkyl); 1.92e2.22 (m, 4H,
CHAlkyl); 2.39e2.65 (m, 5H, CHAlkyl); 5.17e5.25 (m, 2H, CHVinyl);
5.65e5.75 (m, 2H, CHVinyl); 6.59e6.74 (m, 2H, CHVinyl); 6.95 (dd,
3J¼ 7.87 Hz, 4J¼ 1.71 Hz, 1H, CHAr); 7.04 (d, 3J¼ 8.28 Hz, 2H, CHAr);
7.13 (dd, 3J¼ 7.80 Hz, 4J¼ 1.53 Hz, 1H, CHAr); 7.20 (d, 3J¼ 8.19 Hz,
2H, CHAr); 7.26e7.29 (m, 2H, CHAr); 7.34 (dd, 3J¼ 7.91 Hz,
4J¼ 1.79 Hz, 1H, CHAr); 7.44 (d, 3J¼ 8.09 Hz, 1H, CHAr). 13C NMR
(75MHz, CDCl3): d¼ 13.8 (CH3); 21.5, 26.0, 26.6, 28.9, 31.7, 35.8
(CH2); 37.5, 44.9 (CH); 47.9 (C); 50.6 (CH); 113.3, 113.4 (CH2,Vinyl);
124.7 (CHAr); 125.4 (2xCHAr); 125.7, 125.9, 127.5 (CHAr); 129.9
(2xCHAr); 130.4, 130.5 (CHAr); 135.1, 135.2, 135.5 (CAr); 136.5, 136.6
(CHVinyl); 138.8, 139.2, 139.9, 140.0, 141.3 (CAr); 220.8 (C]O). IR
(ATR, cm1): ~n ¼ 2925 (m), 1735 (s), 1627 (w), 1467 (m), 1255 (m),
1006 (m), 987 (m), 848 (m), 821 (s). MS (EI, 70 eV): m/z (%)¼ 459
(40), 458 (Mþ, 100), 291 (11), 55 (12). HRMS (EI, 70 eV): Calculated
for C34H34O (Mþ), 458.26042; measured 458.26005.
4.4.15. 3,4-Bis-(3-thienyl)-13b-estra-1,3,5(10)-trien-17-one [5h]
5h was synthesized according to general procedure B using 3-
thienylboronic acid (0.63mmol, 93mg) and was puriﬁed via col-
umn chromatography (heptane/ethyl acetate 5:1) to yield a brown
solid (80mg, 91%). mp. 195e196 C. 1H NMR (250MHz, CDCl3):
d¼ 0.94 (s, 3H, CH3); 1.53e1.67 (m, 6H, CHAlkyl); 1.95e2.19 (m, 4H,
CHAlkyl); 2.35e2.57 (m, 3H, CHAlkyl); 2.64e2.69 (m, 2H, CHAlkyl);
6.72 (dd, 3J¼ 4.97 Hz, 4J¼ 1.19 Hz, 1H, CHAr); 6.85e6.90 (m, 3H,
CHAr); 7.08 (dd, 3J¼ 4.97 Hz, 4J¼ 2.99 Hz, 1H, CHAr); 7.29 (dd,
3J¼ 4.86 Hz, 4J¼ 2.95 Hz, 1H, CHAr); 7.36e7.38 (m, 2H, CHAr). 13C
NMR (63MHz, CDCl3): d¼ 13.8 (CH3); 21.5, 26.0, 26.6, 28.7, 31.6,
35.8 (CH2); 37.6, 44.8 (CH); 47.9 (C); 50.5 (CH); 122.4, 123.2, 124.0,
124.9, 126.9, 128.7, 129.5 (CHAr); 134.5, 135.2, 136.0, 139.3, 140.3,
142.0 (CAr); 220.7 (C]O). IR (ATR, cm1): ~n ¼ 2929 (m), 1729 (s),
1471 (w),1259 (m),1076 (m),1010 (m), 850 (m), 788 (s), 765 (s), 678
(m).MS (EI, 70 eV): m/z (%)¼ 419 (22), 418 (Mþ, 100), 260 (16), 259
(16), 258 (19), 254 (16), 247 (23), 222 (15), 221 (25), 79 (36), 77 (17),
67 (35), 55 (67), 45 (21), 43 (15), 41 (50), 39 (19), 29 (35). HRMS (EI,
70 eV): Calculated for C26H26OS2 (Mþ), 418.14196; measured
418.14117.
4.4.16. 3-(4-Triﬂuoromethylphenyl)-4-(4-tert-butylphenyl)-13b-
estra-1,3,5(10)-trien-17-one [6a]
6a was synthesized according to general procedure C using 4-
triﬂuoromethylphenylboronic acid (0.281mmol, 53mg) and was
puriﬁed via column chromatography (heptane/ethyl acetate 10:1)
to yield a white solid (85mg, 86%). mp. 176e177 C. 1H NMR
(300MHz, CDCl3): d¼ 0.96 (s, 3H, CH3); 1.29 (s, 9H, CH3,tBu);
1.50e1.71 (m, 6H, CHAlkyl); 1.94e2.18 (m, 4H, CHAlkyl); 2.43e2.68
(m, 5H, CHAlkyl); 6.84 (dd, 3J¼ 8.03 Hz, 4J¼ 1.73 Hz, 1H, CHAr); 7.04
(dd, 3J¼ 8.02 Hz, 4J¼ 1.69 Hz, 1H, CHAr); 7.14 (d, 3J¼ 8.00 Hz, 2H,
S. Jopp et al. / Tetrahedron 74 (2018) 2825e2836 2835CHAr); 7.20 (dd, 3J¼ 8.06 Hz, 4J¼ 1.89 Hz, 1H, CHAr); 7.24e7.29 (m,
2H, CHAr); 7.35 (d, 3J¼ 8.11 Hz, 2H, CHAr); 7.44 (d, 3J¼ 8.04 Hz, 1H,
CHAr). 13C NMR (75MHz, CDCl3): d¼ 13.8 (CH3); 21.5, 26.0, 26.6,
28.9 (CH2); 31.3 (CH3,tBu); 31.7 (CH2); 34.4 (CtBu); 35.8 (CH2); 38.0,
44.9 (CH); 47.9 (C); 50.6 (CH); 124.2 (q, 3J¼ 3.70 Hz, 2xCHAr); 124.3
(q, 1J¼ 271.9 Hz, CF3); 124.6, 124.7, 124.9, 127.1 (CHAr); 127.9 (q,
2J¼ 32.2 Hz, C-CF3); 129.8, 129.9 (CHAr); 130.0 (2xCHAr); 135.5,
136.6, 138.1, 140.0, 140.4 (CAr); 145.7 (q, 5J¼ 1.21 Hz, CAr); 149.8
(CAr); 220.7 (C]O). 19F NMR (282MHz, CDCl3): d¼62.43. IR (ATR,
cm1): ~n ¼ 2951 (w), 1739 (s), 1454 (w), 1322 (s), 1159 (s), 1107 (s),
1063 (m), 815 (m), 618 (m). MS (EI, 70 eV): m/z (%)¼ 531 (37), 530
(Mþ, 100), 516 (36), 515 (100), 57 (21). HRMS (EI, 70 eV): Calculated
for C35H37F3O (Mþ), 530.27910; measured 530.27937.
4.4.17. 3-(4-Methoxyphenyl)-4-(4-tert-butylphenyl)-13b-estra-
1,3,5(10)-trien-17-one [6b]
6b was synthesized according to general procedure C using 4-
methoxyphenylboronic acid (0.281mmol, 43mg) and was puri-
ﬁed via column chromatography (heptane/ethyl acetate 10:1) to
yield a white solid (82mg, 90%). mp. 164e165 C. 1H NMR
(250MHz, CDCl3): d¼ 0.95 (s, 3H, CH3); 1.30 (s, 9H, CH3,tBu);
1.54e1.68 (m, 6H, CHAlkyl); 1.91e2.18 (m, 4H, CHAlkyl); 2.43e2.66
(m, 5H, CHAlkyl); 3.73 (s, 3H, OCH3); 6.65 (d, 3J¼ 8.84 Hz, 2H, CHAr);
6.87 (dd, 3J¼ 8.01 Hz, 4J¼ 1.70 Hz, 1H, CHAr); 6.96 (d, 3J¼ 8.84 Hz,
2H, CHAr); 7.05 (dd, 3J¼ 8.00 Hz, 4J¼ 1.65 Hz, 1H, CHAr); 7.21 (dd,
3J¼ 8.02 Hz, 4J¼ 1.87 Hz, 1H, CHAr); 7.25e7.30 (m, 2H, CHAr); 7.40
(d, 3J¼ 8.31 Hz, 1H, CHAr). 13C NMR (63MHz, CDCl3): d¼ 13.8 (CH3);
21.5, 26.0, 26.7, 29.0 (CH2); 31.4 (CH3,tBu); 31.7 (CH2); 34.4 (CtBu);
35.9 (CH2); 38.0, 44.9 (CH); 47.9 (C); 50.6 (CH); 55.1 (OCH3); 112.8
(2xCHAr); 124.4, 124.5, 124.7, 127.4, 129.8, 130.0 (CHAr); 130.8
(2xCHAr); 134.3, 135.2, 137.3, 138.8, 138.9, 140.4, 149.1, 157.7 (CAr);
220.9 (C]O). IR (ATR, cm1): ~n ¼ 2933 (m), 1736 (s), 1608 (m), 1515
(m), 1465 (m), 1244 (s), 1178 (m), 926 (m), 819 (s), 597 (s). MS (EI,
70 eV):m/z (%)¼ 493 (39), 492 (Mþ, 100), 57 (12).HRMS (EI, 70 eV):
Calculated for C35H40O2 (Mþ), 492.30228; measured 492.30225.
4.4.18. 3-(3-Thienyl)-4-(4-tert-butylphenyl)-13b-estra-1,3,5(10)-
trien-17-one [6c]
6c was synthesized according to general procedure C using 3-
thienylboronic acid (0.281mmol, 36mg) and was puriﬁed via col-
umn chromatography (heptane/ethyl acetate 10:1) to yield a yellow
solid (61mg, 70%). mp. 76e77 C. 1H NMR (250MHz, CDCl3):
d¼ 0.94 (s, 3H, CH3); 1.33 (s, 9H, CH3,tBu); 1.53e1.63 (m, 6H, CHAlkyl);
1.93e2.18 (m, 4H, CHAlkyl); 2.46e2.61 (m, 5H, CHAlkyl); 6.69 (dd,
3J¼ 4.97 Hz, 4J¼ 1.12 Hz, 1H, CHAr); 6.76 (dd, 4J¼ 2.87 Hz,
4J¼ 1.12 Hz, 1H, CHAr); 6.95 (dd, 3J¼ 7.92 Hz, 4J¼ 1.75 Hz, 1H, CHAr);
7.01 (dd, 3J¼ 4.94 Hz, 4J¼ 3.03 Hz, 1H, CHAr); 7.07 (dd, 3J¼ 7.89 Hz,
4J¼ 1.86 Hz, 1H, CHAr); 7.30e7.34 (m, 2H, CHAr); 7.37e7.38 (m, 2H,
CHAr). 13C NMR (63MHz, CDCl3): d¼ 13.8 (CH3); 21.5, 26.0, 26.6,
29.0 (CH2); 31.4 (CH3,tBu); 31.7 (CH2); 34.5 (CtBu); 35.8 (CH2); 38.0,
44.8 (CH); 47.9 (C); 50.6 (CH); 122.7, 123.6,124.5,124.8, 125.0,126.9,
129.1, 129.4, 129.5 (CHAr); 133.9, 135.4, 137.5, 139.2, 140.2, 142.9,
149.5 (CAr); 220.8 (C]O). IR (ATR, cm1): ~n ¼ 2925 (m), 1737 (s),
1511 (w), 1463 (m), 1361 (m), 1257 (m), 1006 (m), 829 (s), 790 (s),
649 (m).MS (EI, 70 eV):m/z (%)¼ 469 (35), 468 (Mþ, 100), 453 (22),
247 (19), 57 (20). HRMS (EI, 70 eV): Calculated for C32H36OS (Mþ),
468.24814; measured 468.24721.
4.4.19. 3-(4-Vinylphenyl)-4-(4-tert-butylphenyl)-13b-estra-
1,3,5(10)-trien-17-one [6d]
6c was synthesized according to general procedure C using 4-
vinylphenylborinic acid (0.281mmol, 42mg) and was puriﬁed via
column chromatography (heptane/ethyl acetate 10:1) to yield a
colourless oil (88mg, 97%). 1H NMR (300MHz, CDCl3): d¼ 0.95 (s,
3H, CH3); 1.29 (s, 9H, CH3,tBu); 1.52e1.70 (m, 6H, CHAlkyl); 1.92e2.18(m, 5H, CHAlkyl); 2.43e2.66 (m, 4H, CHAlkyl); 5.17 (dd, 3J¼ 10.90 Hz,
2J¼ 0.74 Hz, 1H, CH]CH2,cis); 5.66 (dd, 3J¼ 17.61 Hz, 2J¼ 0.81 Hz,
1H, CH]CH2,trans); 6.63 (dd, 3J¼ 17.62 Hz, 3J¼ 10.90 Hz, 1H, CH]
CH2); 6.88 (dd, 3J¼ 8.03 Hz, 4J¼ 1.89 Hz, 1H, CHAr); 7.01 (d,
3J¼ 8.26 Hz, 2H, CHAr); 7.06 (dd, 3J¼ 8.05 Hz, 4J¼ 1.87 Hz, 1H,
CHAr); 7.14e7.22 (m, 3H, CHAr); 7.27 (d, 3J¼ 8.70Hz, 2H, CHAr); 7.42
(d, 3J¼ 8.20 Hz, 1H, CHAr). 13C NMR (75MHz, CDCl3): d¼ 13.8 (CH3);
21.5, 26.0, 26.7, 29.0 (CH2); 31.4 (CH3,tBu); 31.7 (CH2); 34.4 (CtBu);
35.8 (CH2); 38.0, 44.9 (CH); 47.9 (C); 50.6 (CH); 113.2 (CH2,Vinyl);
124.5, 124.5,124.8 (CHAr); 125.2 (2xCHAr); 127.4, 129.8 (CHAr); 129.9
(2xCHAr); 135.0, 135.3 (CAr); 136.6 (CHVinyl); 137.1138.9, 139.2, 140.3,
141.5, 149.2 (CAr); 220.8 (C]O). IR (ATR, cm1): ~n ¼ 2940 (m), 1737
(s), 1511 (w), 1464 (m), 1257 (m), 1006 (m), 905 (m), 820 (s).MS (EI,
70 eV):m/z (%)¼ 489 (38), 488 (Mþ, 100), 474 (10), 473 (27), 57 (11).
HRMS (EI, 70 eV): Calculated for C36H40O (Mþ), 488.30737;
measured 488.30708.
4.4.20. 3-(Phenylethynyl)-4-(4-tert-butylphenyl)-13b-estra-
1,3,5(10)-trien-17-one [7]
4d (0.42mmol, 225mg), phenylacetylene (0.50mmol, 51mg),
diisopropylamine (1.26mmol,127mg), Pd(PPh3)4 (10mol%, 48mg),
CuI (10mol%, 8mg) and DMF (6mL) were heated in a pressure tube
under argon atmosphere at 100 C for 20 h. The reaction was
quenched with water (10mL) and extracted with ethyl acetate
(3 20mL). The organic phasewas dried with Na2SO4 and ﬁltrated.
The crude product was puriﬁed by column chromatography (hep-
tane/ethyl acetate 10:1) to yield a yellow solid (119mg, 58%). mp.
186e187 C. 1H NMR (300MHz, CDCl3): d¼ 0.95 (s, 3H, CH3); 1.43
(s, 9H, CH3,tBu); 1.52e1.64 (m, 6H, CHAlkyl); 1.92e2.21 (m, 4H,
CHAlkyl); 2.39e2.67 (m, 5H, CHAlkyl); 6.97e7.01 (m, 2H, CHAr);
7.17e7.34 (m, 6H, CHAr); 7.42e7.52 (m, 3H, CHAr). 13C NMR (75MHz,
CDCl3): d¼ 13.8 (CH3); 21.5, 25.9, 26.4, 28.6 (CH2); 31.5 (CH3,tBu);
31.6 (CH2); 34.6 (CtBu); 35.8 (CH2); 37.5, 44.9 (CH); 47.9 (C); 50.6
(CH); 89.9, 92.5 (C^C); 121.1, 123.6 (CAr); 124.2, 124.8, 124.9, 127.6
(CHAr); 127.9 (2xCHAr); 128.4, 129.0, 129.3 (CHAr); 131.2 (2xCHAr);
134.9, 137.6140.5, 144.7, 149.6 (CAr); 220.7 (C]O). IR (ATR, cm1): ~n
¼ 2939 (m), 1738 (s), 1493 (w), 1257 (w), 1112 (w), 1007 (m), 834
(m), 757 (s), 691 (s).MS (EI, 70 eV):m/z (%)¼ 487 (16), 485 (Mþ, 39),
430 (100), 429 (66), 307 (10), 303 (12), 291 (12), 289 (13), 266 (22),
265 (58), 57 (24). HRMS (EI, 70 eV): Calculated for C36H38O (Mþ),
486.29172; measured 486.29159.
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